Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments NEW HAVEN, Conn., May 12, 2025 /PRNewswire/ – Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life- changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a review of recent accomplishments and antici ...

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Biohaven Ltd. (NYSE: BHVN ) is a clinical-stage biopharmaceutical that develops treatments for neurol ...

Core Insights - Biohaven's shares surged approximately 8% following the announcement of a $600 million non-dilutive financing deal with Oberland Capital [1][2] - The financing includes an immediate $250 million, with the remainder contingent on regulatory milestones and strategic acquisitions [2] - The funding aims to support clinical trials and prepare for potential FDA approval of Biohaven's lead candidate, troriluzole, for spinocerebellar ataxia (SCA) [2][3] Financial Details - The total financing deal is valued at up to $600 million, with $250 million available immediately [2] - Biohaven's market capitalization was around $3 billion prior to the financing announcement [4] - The non-dilutive nature of the deal means existing shareholders will not see their ownership percentage decrease [2][4] Product Development - Troriluzole is Biohaven's primary candidate targeting SCA, a rare neurological condition with no current approved therapies [3] - The funding provides Biohaven with significant resources to advance late-stage development of its drug pipeline, which also includes oncology and immunology treatments [3] - The potential FDA approval of troriluzole could significantly enhance Biohaven's valuation [4]

Core Viewpoint - Biohaven Ltd. has entered into a significant investment agreement with Oberland Capital Management for up to $600 million, aimed at supporting ongoing clinical trials and commercialization efforts for its product, troriluzole, targeting spinocerebellar ataxia (SCA) [1][2][3] Group 1: Investment Details - The agreement includes an initial funding of $250 million to be provided at closing on or before April 30, 2025 [1][6] - An additional $150 million is contingent upon FDA approval of troriluzole, with further funding of up to $200 million available for strategic acquisitions and related expenses [3][6] - The investment is structured as a Note Purchase Agreement (NPA) that is non-dilutive to existing shareholders [3][6] Group 2: Product and Market Potential - Troriluzole is a novel prodrug designed to modulate glutamate levels, which has potential applications in various diseases beyond SCA [5][8] - The investment will facilitate the advancement of Biohaven's pipeline, which includes five innovative platforms across immunology, neuroscience, and oncology [3][8] Group 3: Strategic Partnership - Oberland Capital expresses confidence in Biohaven's ability to address unmet needs in rare diseases and is committed to supporting the launch of troriluzole [3][9] - The partnership is expected to leverage Oberland's expertise in funding rare disease product launches, enhancing Biohaven's operational capabilities [3][9]

Core Viewpoint - Biohaven's withdrawal of its application for the investigational drug Dazluma from the European Medicines Agency led to a significant decline in its stock price, dropping over 15% despite a generally bullish market on that day [1][2]. Group 1: Company Actions - Biohaven's subsidiary withdrew its application for marketing authorization for Dazluma on March 24, as announced by the European Medicines Agency [2]. - The company originally applied for authorization for Dazluma at the end of 2023, targeting spinocerebellar ataxia type 3, a rare genetic nerve cell affliction [3]. - Biohaven indicated in a letter to the EMA that it plans to generate additional data to support a new application for the drug once the data is available [4]. Group 2: Regulatory Context - The EMA had prepared a series of questions regarding Dazluma and noted several issues that hindered its approval [3]. - The withdrawal from a regulatory submission is viewed as a significant setback for investor confidence, especially given the large patient pool in the European Union [4].

LOS ANGELES, April 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biohaven announced its financial results for Q4 and full year 2024 on March 3, 2025. ...

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 3, 2025 ...

Core Insights - Biohaven Ltd. will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, showcasing its innovative neuroscience pipeline across various development programs [1][2] Company Developments - The presentations include 3 oral and 10 poster presentations, focusing on potential first-in-class therapies for neurological disorders with high unmet needs [2] - Biohaven's pipeline includes Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation [1][6] Oral Presentations - BHV-8000, a selective TYK2/JAK1 inhibitor, shows efficacy in a Parkinson's disease mouse model [3] - BHV-2100, a first-in-class TRPM3 antagonist, demonstrates safety and tolerability for pain and migraine [3] - Novel bispecific degrader BHV-1310 achieves significant IgG reduction in preclinical models [3] Poster Presentations - A qualitative assessment of the epilepsy patient experience through social media [4] - BHV-2100's development for migraine treatment [5] - A modern design for a Phase 2/3 study evaluating BHV-7000 in idiopathic generalized epilepsy [5] Company Overview - Biohaven focuses on discovering and developing treatments in immunology, neuroscience, and oncology, leveraging its drug development experience and proprietary platforms [6]

Shares of early-stage biotech stocks, including Biohaven (BHVN -8.53%), Recursion Pharmaceuticals (RXRX -6.62%), and CRISPR Therapeutics (CRSP -3.22%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence .The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study. In addition, all money-losing biotechs sold off hard along with ...

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, an ...